Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.Thomas U. Marron, Jamal Misleh, Alexander I. Spira et al.|Journal of Clinical Oncology|2025Cited by 1